Virtual Library
Start Your Search
M. Ohillips
Author of
-
+
P1.03 - Poster Session with Presenters Present (ID 455)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Radiology/Staging/Screening
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.03-077 - Analysis of the Early CDT-Blood Biomarker for Lung Cancer in Higher vs. Lower Risk Cohorts (ID 5079)
14:30 - 14:30 | Author(s): M. Ohillips
- Abstract
Background:
The Early Cancer Detection Test (CDT)-Lung Cancer Screening (LCS) Study is a prospective, lung cancer screening study testing the hypothesis that a serum biomarker consisting of a panel of seven cancer-associated autoantibodies, in combination with a low-dose CT (LDCT), would increase detection of early stage lung cancer. We analyzed nodules rates and lung cancer in “higher risk” individuals who meet the USPSTF LCS criteria (http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening) and “lower risk” individuals who do not meet these criteria.
Methods:
The EarlyCDT LCS study eligibility criteria included persons 50-75 years of age, current or former smokers of ≥ 20 pack years, former smokers have ˂ 10 years since quit smoking. Additionally, those with a history of lung cancer in first-degree relative(s) and any history of smoking were also included. Exclusion criteria included any history of cancer within 10 years (except skin cancer), any use of oxygen, or life expectancy < 5 years. The EarlyCDT-Lung test was considered positive if any one of the seven autoantibodies was positive.
Results:
From May 2012 through June 2016, 1235 individuals were enrolled (final target 1600). The median age was 59 years, 55% were female and 45% were male. Fifty-two per cent were current smokers while 48% were former smokers. Fifty-three percent of participants were higher risk and 47% were lower risk. The EarlyCDT-Lung was positive in 8% of higher risk individuals and 6% of lower risk individuals. Thirty-five per cent of higher risk individuals had nodules on LDCT while 27% of lower risk participants had nodules on LDCT. The EarlyCDT-Lung blood test was positive in 91 patients, 77 were higher risk and 34 were lower risk. There were 7 lung cancers, all in the higher risk group, resulting in a lung cancer rate of 1.07% in the higher risk group. The median pack years of individuals with lung cancer was 60 and the median age was 64 years. Two of the 7 lung cancer patients were positive for the EarlyCDT test. The relative risk of lung cancer in patients with a positive EarlyCDT test was 5.5 for the entire cohort and 4.5 for the higher risk group for lung cancer.
Conclusion:
There were more total nodules in the higher risk group compared to the lower risk group. There were more lung cancers in the higher risk group compared with the lower risk group. A positive EarlyCDT test is associated with an increased risk of lung cancer.
